INSMED INC (INSM) Current Ratio
- Current ratio · latest quarter: Value 3.72×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.72× | Current assets / current liabilities. $1.63B ÷ $438.74M ≈ 3.72× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.63B USD | Assets, Current |
| Current obligations | 438.74M USD | Liabilities, Current |
| Cash and equivalents | 544.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 615.55M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 215.32M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 142.38M USD | Inventory, Net |
| Payables | 74.56M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.63B | $438.74M | $544.76M | $615.55M | $215.32M | $142.38M | $74.56M | (m) | 3.72× |
| 2026-03-31 | $1.61B | $361.01M | $582.19M | $641.33M | $178.56M | $132.91M | $73.38M | (m) | 4.47× |
| 2025-12-31 | $1.79B | $468.87M | $510.44M | $919.60M | $140.86M | $132.07M | $79.91M | (m) | 3.83× |
| 2025-09-30 | $1.93B | $417.21M | $334.76M | $1.35B | $65.26M | $120.97M | $79.59M | (m) | 4.63× |
| 2025-06-30 | $2.08B | $311.68M | $1.28B | $572.44M | $55.03M | $107.61M | $74.05M | (m) | 6.68× |
| 2025-03-31 | $1.40B | $239.23M | $403.25M | $796.20M | $47.75M | $100.71M | $57.68M | (m) | 5.86× |
| 2024-12-31 | $1.62B | $297.53M | $555.03M | $878.80M | $52.01M | $98.58M | $73.03M | (m) | 5.45× |
| 2024-09-30 | $1.65B | $259.19M | $461.45M | $1.01B | $42.32M | $98.47M | $64.95M | (m) | 6.37× |
| 2024-06-30 | $1.42B | $524.15M | $1.25B | $0.00 | $40.30M | $90.06M | $51.36M | $224.45M | 2.71× |
| 2024-03-31 | $758.72M | $420.86M | $595.73M | $0.00 | $37.16M | $82.96M | $44.02M | $224.19M | 1.80× |
| 2023-12-31 | $929.06M | $225.63M | $482.37M | $298.07M | $41.19M | $83.25M | $65.39M | (m) | 4.12× |
| 2023-09-30 | $926.58M | $196.73M | $487.11M | $298.84M | $35.58M | $77.92M | $65.38M | (m) | 4.71× |
| 2023-06-30 | $1.05B | $204.26M | $612.88M | $304.89M | $30.95M | $77.35M | $55.70M | (m) | 5.15× |
| 2023-03-31 | $1.13B | $187.98M | $968.91M | $29.77M | $30.52M | $71.32M | $56.67M | (m) | 6.01× |
| 2022-12-31 | $1.27B | $190.24M | $1.07B | $74.24M | $29.71M | $69.92M | $50.46M | (m) | 6.69× |
| 2022-09-30 | $632.16M | $137.65M | $414.63M | $98.66M | $27.40M | $66.28M | $11.58M | (m) | 4.59× |
| 2022-06-30 | $674.73M | $113.82M | $416.08M | $138.79M | $29.48M | $67.02M | $31.14M | (m) | 5.93× |
| 2022-03-31 | $756.14M | $125.25M | $515.70M | $119.42M | $25.72M | $64.14M | $48.57M | (m) | 6.04× |
| 2021-12-31 | $837.04M | $135.17M | $716.78M | $0.00 | $24.35M | $67.01M | $35.78M | (m) | 6.19× |
| 2021-09-30 | $958.98M | $112.50M | $846.56M | (m) | $19.32M | $67.45M | $23.53M | (m) | 8.52× |
| 2021-06-30 | $1.04B | $99.66M | $928.33M | (m) | $18.42M | $60.38M | $31.08M | (m) | 10.42× |
| 2021-03-31 | $501.00M | $81.40M | $409.75M | (m) | $17.63M | $52.06M | $22.42M | (m) | 6.16× |
| 2020-12-31 | $622.89M | $118.81M | $532.76M | (m) | $16.56M | $49.59M | $42.85M | (m) | 5.24× |
| 2020-09-30 | $667.15M | $83.90M | $588.75M | (m) | $15.20M | $43.48M | $22.15M | (m) | 7.95× |
| 2020-06-30 | $707.31M | $78.75M | $641.91M | (m) | $15.17M | $35.47M | $25.00M | (m) | 8.98× |
| 2020-03-31 | $492.51M | $71.53M | $428.94M | (m) | $17.15M | $30.64M | $18.19M | (m) | 6.89× |
| 2019-12-31 | $555.19M | $85.24M | $487.43M | (m) | $19.23M | $28.31M | $13.18M | (m) | 6.51× |
| 2019-09-30 | $595.60M | $85.39M | $535.63M | (m) | $15.35M | $23.31M | $20.41M | (m) | 6.97× |
| 2019-06-30 | $648.91M | $86.03M | $601.26M | (m) | $11.64M | $20.16M | $17.03M | (m) | 7.54× |
| 2019-03-31 | $454.63M | $94.25M | $420.23M | (m) | $9.35M | $12.68M | $30.22M | (m) | 4.82× |
| 2018-12-31 | $518.95M | $79.73M | $495.07M | (m) | $5.51M | $7.03M | $17.74M | (m) | 6.51× |
| 2018-09-30 | $577.50M | $57.42M | $567.57M | (m) | (m) | (m) | $16.58M | (m) | 10.06× |
| 2018-06-30 | $645.26M | $45.64M | $634.33M | (m) | (m) | (m) | $15.97M | (m) | 14.14× |
| 2018-03-31 | $696.41M | $34.81M | $686.58M | (m) | (m) | (m) | $13.18M | (m) | 20.01× |
| 2017-12-31 | $389.44M | $44.66M | $381.17M | (m) | $0.00 | $0.00 | $14.67M | (m) | 8.72× |
| 2017-09-30 | $437.48M | $28.77M | $430.68M | (m) | (m) | (m) | $9.35M | (m) | 15.21× |
| 2017-06-30 | $96.53M | $26.27M | $91.06M | (m) | (m) | (m) | $11.03M | (m) | 3.67× |
| 2017-03-31 | $131.62M | $23.27M | $125.84M | (m) | (m) | (m) | $8.45M | (m) | 5.66× |
| 2016-12-31 | $168.41M | $27.99M | $162.59M | (m) | (m) | (m) | $10.44M | (m) | 6.02× |
| 2016-09-30 | $206.30M | $23.46M | $200.52M | (m) | (m) | (m) | $8.28M | (m) | 8.79× |
| 2016-06-30 | $229.31M | $32.32M | $223.11M | (m) | (m) | (m) | $9.40M | $8.69M | 7.09× |
| 2016-03-31 | $258.49M | $25.54M | $252.87M | (m) | (m) | (m) | $8.69M | $5.67M | 10.12× |
| 2015-12-31 | $288.12M | $22.26M | $282.88M | (m) | (m) | (m) | $7.47M | $3.11M | 12.94× |
| 2015-09-30 | $319.26M | $46.70M | $310.97M | (m) | (m) | (m) | $10.86M | $25.26M | 6.84× |
| 2015-06-30 | $342.09M | $43.07M | $335.03M | (m) | (m) | (m) | $8.68M | $25.12M | 7.94× |
| 2015-03-31 | $140.24M | $41.13M | $134.55M | (m) | (m) | (m) | $7.86M | $24.99M | 3.41× |
| 2014-12-31 | $164.71M | $19.63M | $159.23M | (m) | (m) | (m) | $9.25M | (m) | 8.39× |
| 2014-09-30 | $170.84M | $21.28M | $167.31M | (m) | (m) | (m) | $8.87M | $5.18M | 8.03× |
| 2014-06-30 | $86.71M | $21.82M | $82.70M | (m) | (m) | (m) | $11.41M | $3.28M | 3.97× |
| 2014-03-31 | $106.21M | $20.00M | $101.25M | (m) | (m) | (m) | $9.82M | $5.19M | 5.31× |
| 2013-12-31 | $116.16M | $16.46M | $113.89M | (m) | (m) | (m) | $5.93M | $3.28M | 7.06× |
| 2013-09-30 | $129.75M | $19.82M | $128.03M | (m) | (m) | (m) | $4.66M | $7.05M | 6.55× |
| 2013-06-30 | $78.57M | $18.10M | $74.59M | (m) | (m) | (m) | $7.87M | $4.65M | 4.34× |
| 2013-03-31 | $83.03M | $20.27M | $79.43M | (m) | (m) | (m) | $8.18M | $4.88M | 4.10× |
| 2012-12-31 | $93.58M | $15.75M | $90.78M | (m) | (m) | (m) | $7.06M | $3.01M | 5.94× |
| 2012-09-30 | $90.35M | $6.54M | $44.99M | (m) | $0.00 | (m) | $2.98M | (m) | 13.80× |
| 2012-06-30 | $73.85M | $6.49M | $28.57M | (m) | $0.00 | (m) | $3.20M | (m) | 11.39× |
| 2012-03-31 | $70.96M | $4.14M | $22.04M | (m) | $0.00 | (m) | $2.88M | (m) | 17.16× |
| 2011-12-31 | $77.40M | $4.48M | $14.85M | (m) | $757.00K | (m) | $2.33M | $0.00 | 17.29× |
| 2011-09-30 | $83.98M | $3.68M | $10.45M | (m) | $440.00K | (m) | $1.50M | (m) | 22.81× |
| 2011-06-30 | $92.62M | $3.49M | $9.84M | (m) | $303.00K | (m) | $1.92M | (m) | 26.52× |
| 2010-12-31 | $108.80M | $3.34M | $10.74M | (m) | $471.00K | (m) | $1.45M | (m) | 32.58× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |